A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy
Advanced Science · 2026-06 · 13 (34)
DOI: 10.1002/advs.202523024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.05.2026. Verfasst von Shugang Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer C…. Hauptthemen laut MEDLINE: Dendritic Cells, Single-Domain Antibodies, Immunotherapy, Cancer Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Project for Disciplines of Excellence from West China Hospital, Sichuan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Effective cancer immunotherapy requires not only efficient antigen delivery to dendritic cells (DCs) but also overcoming local immunosuppression. Here, we introduce a nanobody‐LNP platform that achieves both targeting and active relicensing of DCs. By decorating lipid nanoparticles with nanobodies against the DC surface protein Plastin‐2 (PLS2), our platform achieves a remarkable 93% internalization efficiency. This preferential targeting dramatically enhances antigen expression while simultaneously relicensing DCs toward a more potent, mature phenotype by inhibiting the immunosuppressive Leptin‐JAK2‐STAT3 signaling pathway. This integrated strategy unleashed potent cytotoxic T lymphocyte responses and led to marked inhibition of established tumors. Our work establishes PLS2 as a novel immunomodulatory receptor and presents a dual‐action delivery platform that significantly boosts cancer vaccine potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Experimental Research, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Xiangrong Song
Förderung
- National Key Research and Development Program of China
- Project for Disciplines of Excellence from West China Hospital, Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Qin, S., Huang, Z., Huang, H., Zhang, Y., Chen, Y., He, X., Niu, Z., Xiang, Z., Zou, C., & Song, X. (2026). A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy. Advanced Science, 13(34). https://doi.org/10.1002/advs.202523024
Vancouver
Qin S, Huang Z, Huang H, Zhang Y, Chen Y, He X, et al. A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy. Advanced Science. 2026;13(34). doi:10.1002/advs.202523024
BibTeX
@article{Qin2026,
author = {Qin, Shugang and Huang, Zhiying and Huang, Hai and Zhang, Yupei and Chen, Yuting and He, Xi and Niu, Zhenyi and Xiang, Zhongzheng and Zou, Chaoyu and Song, Xiangrong},
title = {A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {34},
doi = {10.1002/advs.202523024}
}
EUVIMED